Roche's Latest Drug Marks a Milestone in KRAS-Driven Lung Cancer Treatment
Roche's new drug has been approved, potentially setting a new standard for treating KRAS-driven lung cancer, amidst a thriving biotech sector.
Editorial Staff
1 min read
Updated 11 days ago
Roche has received approval for a new drug aimed at treating KRAS-driven lung cancer, which could represent a significant advancement in oncology.
This development is noteworthy as it may redefine treatment protocols for a challenging subset of lung cancer patients.
In related news, Vertex is expanding its gene therapy offerings, reflecting the ongoing growth and optimism within the biotech industry.
Updates
Update at 14:13 UTC on 2026-07-02
STAT reported Biotech's bull market, Vertex's gene therapy expansion, and more news from The Readout.
Sources: STAT